Only modest benefits from starting HIV therapy with a CD4 cell count above 500 compared to 350
Abacavir and cardiovascular risk: contradictory findings continue to emerge, mechanisms still unclear
Heart attacks, non-AIDS cancers, more common in Botswana than in US patients on HIV treatment
Treatment is prevention: now, how do we make it work?
HIV damages B-cells as well as T-cells: new treatment targets identified
Tropism impacts on virological success of first-line HIV therapy
Switch from efavirenz to raltegravir improves mood and lipid profiles
Hair concentrations of atazanavir are associated with the success of HIV treatment
Treatment as prevention works!
